These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27379978)

  • 1. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
    Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
    J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
    Chan S; Zhang Y; Wang J; Yu Q; Peng X; Zou J; Zhou L; Tan L; Duan Y; Zhou Y; Hur H; Ai J; Wang Z; Ren X; Zhang Z; Ding K
    J Med Chem; 2022 Nov; 65(22):15374-15390. PubMed ID: 36358010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
    Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
    Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors.
    Tan L; Zhang Z; Gao D; Chan S; Luo J; Tu ZC; Zhang ZM; Ding K; Ren X; Lu X
    Eur J Med Chem; 2019 Mar; 166():318-327. PubMed ID: 30731400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
    Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
    J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
    Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
    Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
    Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent discovery and development of AXL inhibitors as antitumor agents.
    Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
    Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment.
    Li MC; Lai YL; Kuo PH; Reddy JS; Chen CM; Manimala J; Wang PC; Wu MS; Chang CY; Yang CM; Lin CY; Huang YC; Chiu CH; Chang L; Lin WH; Yeh TK; Yen WC; Hsieh HP
    J Med Chem; 2024 Jul; 67(13):10906-10927. PubMed ID: 38913493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and identification of novel compounds with potential anti-proliferative effects on gallium-resistant lung cancer through an AXL kinase pathway.
    Oyewumi MO; Alazizi A; Liva S; Lin L; Geldenhuys WJ
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4553-4556. PubMed ID: 25131538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
    Choi MJ; Roh EJ; Hur W; Lee SH; Sim T; Oh CH; Lee SH; Kim JS; Yoo KH
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3761-3765. PubMed ID: 30340900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
    Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
    Yu Y; Jang M; Miyashiro J; Clark RF; Zhu GD; Gong J; Dai Y; Frey RR; Penning TD; Kim H; Lee HK; Kim JK; Ryu KM; Park SJ; Yoon T; Li T; Kurnick MD; Kapecki NJ; Li L; Gorman JV; Montgomery DA; Manaves V; Bromberg KD; Doktor SZ; Thakur A; Wang J; Smith HA; Buchanan FG; Ferguson DC; Torrent M; Jakob CG; Qiu W; Upadhyay AK; Martin RL; Lai A; Michaelides MR
    J Med Chem; 2024 Oct; 67(19):17000-17032. PubMed ID: 39283694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.